RTI Surgical has unveiled its new corporate identity as Evergen, signaling its strategic evolution into a premier Contract Development and Manufacturing Organization (CDMO) providing biosolutions in regenerative medicine.
 
The rebranding follows a transformative year marked by the acquisitions of Cook Biotech and Collagen Solutions, establishing Evergen as a CDMO offering a comprehensive portfolio of allograft and xenograft biomaterials at scale.
 
The new identity embodies Evergen’s commitment to innovation, quality, and patient-centered solutions in regenerative medicine. This strategic repositioning reinforces the company’s dedication to setting new industry benchmarks through customized solutions for its customers across key high-growth therapeutic areas including cardiac, sports medicine, orthopedic surgery, neurosurgery, plastic and reconstructive surgery.
 
Olivier Visa, President and CEO, Evergen, said: “This rebranding marks a defining moment in our company’s evolution. Every decision we make begins with understanding patient needs and developing flexible, high-quality solutions that enable our customers to meet these needs effectively. As Evergen, we are positioned to lead a new era of regenerative medicine by becoming the trusted CDMO of choice for OEM partners.”
 
Kim Spooner, Chief People Officer, Evergen, added: “Our new brand identity honors our rich heritage and unifies our employees as we become one team. As the newer businesses have integrated, it has been clear that there is a strong cultural affinity across our teams. I look forward to seeing how this further strengthens in the months and years ahead.”